development aspects

ALTO-203 Misses Depression Endpoint but Shows Positive Biomarker and Cognitive Signals

6 days ago talkbio0Tagged ALTO-203, Attention, Biological Markers, development aspects, drug activity, Electroencephalography, Neuroscience discipline, theta/beta ratio, Wakefulness, William Blair

ALTO-203; Alto Neuroscience; Phase 2 trial; major depressive disorder; EEG biomarkers; theta/beta ratio; attention; wakefulness; William Blair; drug activity; future development

FDA Reinstates Generic Drug Policy Group After April Firings

3 weeks ago talkbio0Tagged Administrative action, Departure - action, development aspects, drug price, Generic Drugs, layoffs, Office, Policy, reinstatement, Transection (procedure), United States Food and Drug Administration

FDA; generic drugs; policy office; Division of Policy Development; reinstatement; layoffs; drug prices; administrative leave

Sanofi Announces $20 Billion US Investment Over Five Years

2 months ago talkbio0Tagged Big Pharma, development aspects, domestic partnerships, Drug Industry, Investments, Manufacturing, research, sanofi, Surgical construction, tariffs, U.S.

Sanofi; $20 billion investment; US pharmaceutical industry; manufacturing; research and development; tariffs; job creation; Big Pharma; domestic partnerships

Thermo Fisher jumps on the US investment bandwagon with $2B in additional spending

2 months ago talkbio0Tagged development aspects, Investments, Manufacture, Martes pennanti, Science, Thermo Fisher, United States

United States, Investments, Manufacture, Martes pennanti, Science, development aspects, Thermo Fisher

Sanofi pens $1.8B research deal for 2 bispecific antibodies aimed at autoimmune, immunology

3 months ago talkbio0Tagged Antibodies, Bispecific, Autoimmune, Collaboration, development aspects, Earendil Labs, Immunology, Inflammatory Bowel Diseases, sanofi

Antibodies, Bispecific, Autoimmune, Inflammatory Bowel Diseases, sanofi, Earendil Labs, Immunology, Collaboration, development aspects

HHS Terminates Funding for GeoVax’s Next-Generation COVID-19 Vaccine: Impacts and Developments

3 months ago talkbio0Tagged BARDA, CHARGE Syndrome, Clinical Trials, COVID19 (disease), development aspects, GeoVax, Immunocompromised Host, pandemic preparedness, Project NextGen, Termination - Inactive Reason Code, Vaccines

GeoVax, HHS, BARDA, Project NextGen, COVID-19 vaccine, GEO-CM04S1, clinical trials, funding termination, immunocompromised, vaccine development, pandemic preparedness

Isomorphic Labs raises $600M to push AI-designed drugs into clinic

3 months ago talkbio0Tagged AI-designed, development aspects, Isomorphous, Laboratory test finding

Isomorphous, Laboratory test finding, development aspects, AI-designed

Beyond Black Box: How Data-Driven AI Is Transforming RNA Medicine Development

3 months ago talkbio0Tagged Aortic Valve Insufficiency, black box, Clinical Trials, Data-Driven AI, datasets, development aspects, Drug Design, RNA medicine, Transforming RNA Medicine Development

Aortic Valve Insufficiency, development aspects, RNA medicine, black box, Data-Driven AI, Transforming RNA Medicine Development, datasets, Drug Design, Clinical Trials

MacroGenics Discontinues Development of Vobra Duo ADC After Phase 2 Prostate Cancer Trial Results

3 months ago talkbio0Tagged Antibody-Drug Conjugates, CD276 gene, concerns, development aspects, discontinued, Larix, MacroGenics, Malignant neoplasm of prostate, Safety, vobra

MacroGenics, vobra duo, antibody-drug conjugate, B7-H3, prostate cancer, TAMARACK trial, discontinued development, safety concerns

Samsung Biologics Embarks on New Phase of Growth with Bio Campus II and ADC Services

6 months ago talkbio0Tagged Antibody-Drug Conjugates, Bio Campus II, Biological Factors, Capacity, CDMO, Contract agreement, development aspects, digital transformation, expansion, Manufacturing Organization, Plants, Samsung, Services

Samsung Biologics, Bio Campus II, Plant 5, antibody-drug conjugate (ADC) services, capacity expansion, digital transformation, contract development and manufacturing organization (CDMO)